Research On New Treatment For Neglected Disease
Phase 3 research wa published related to its first approved drug product, Paromomycin IM Injection (Paromomycin).
This clinical trial shows that the medicine paromomycin is safe, effective, and well suited to curing visceral leishmaniasis (VL), the world's second most deadly parasitic disease after malaria.
The Institute for OneWorld Health, working closely with the Indian Council for Medical Research (ICMR) sponsored the clinical trial in collaboration with the Special Programme for Research and Training in Tropical Diseases (TDR), a Geneva-based international organization sponsored by UNICEF, UNDP, the World Bank and the World Health Organization. The clinical trial was established with funding from the Bill & Melinda Gates Foundation.
Gland Pharma Limited, the Hyderabad, India-based drug manufacturer, working with OneWorld Health and other collaborators, received regulatory approval from the Drug-Controller General - India (DCGI) for Paromomycin IM Injection as a treatment for VL on August 31, 2006. Gland Pharma has agreed to act as the global manufacturer of Paromomycin to ensure access to all those that need it, and at a markedly reduced cost